NCT03750565View on ClinicalTrials.gov

Multiple Dose Ethnobridging PK Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 27, 2018

Primary Completion Date

February 13, 2019

Study Completion Date

February 13, 2019

Conditions
Inflammatory Bowel DiseasesIBD
Interventions
DRUG

TD-1473 - Dose A

oral capsule/tablet, QD

DRUG

TD-1473 - Dose B

oral capsule/tablet, QD

DRUG

TD-1473 - Dose C

oral capsule/tablet, QD

DRUG

Placebo

oral capsule/tablet, QD

Trial Locations (1)

90630

Theravance Biopharma Investigational Site, Cypress

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY

NCT03750565 - Multiple Dose Ethnobridging PK Study in Healthy Subjects | Biotech Hunter | Biotech Hunter